Natural Product (NP) Details
General Information of the NP (ID: NP4688) | |||||
---|---|---|---|---|---|
Name |
Methyl gallate
|
||||
Synonyms |
METHYL GALLATE; Methyl 3,4,5-trihydroxybenzoate; 99-24-1; Gallic acid methyl ester; Methylgallate; Benzoic acid, 3,4,5-trihydroxy-, methyl ester; Gallic acid, methyl ester; methyl galloate; MFCD00002194; UNII-623D3XG80C; 3,4,5-Trihydroxybenzoic acid methyl ester; AI3-00861; 3,4,5-Trihydroxy-benzoic acid methyl ester; CHEMBL65675; 623D3XG80C; NSC363001; Methyl 3,4,5-trihydroxybenzoate, 99%; GALLINCIN; CCRIS 5567; EINECS 202-741-7; NSC 363001; BRN 2113180; Methyl gallate;; methyl-3,4,5-trihydroxybenzoate; Gallic acid methyl; ACMC-209sc1; cid_7428; SCHEMBL39513; 4-10-00-01998 (Beilstein Handbook Reference); MLS000574912; DTXSID3059189; ZINC21789; CHEBI:145828; HMS2210A23; HMS3346G16; ACT10740; HY-N2010; ANW-40991; BBL010505; BDBM50187133; CM0133; s3790; SBB064246; STL146151; methyl 3,4,5-tris(oxidanyl)benzoate; AKOS000277450; CCG-266463; EBD1614516; MCULE-4626719858; NSC-363001; Methyl 3,4,5-trihydroxybenzoate, 98%; NCGC00247606-01; AC-11364; AK-94175; AS-14808; M666; SMR000156263; SY011144; AB0007856; DB-057768; CS-0018330; FT-0626596; G0017; H6235; ST50825211; A845986; CS-008/03903045; W-100047; Q15425833
Click to Show/Hide
|
||||
Species Origin | Givotia rottleriformis ... | Click to Show/Hide | |||
Givotia rottleriformis | |||||
Disease | Brain cancer [ICD-11: 2A00] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C8H8O5
|
||||
PubChem CID | |||||
Canonical SMILES |
COC(=O)C1=CC(=C(C(=C1)O)O)O
|
||||
InChI |
1S/C8H8O5/c1-13-8(12)4-2-5(9)7(11)6(10)3-4/h2-3,9-11H,1H3
|
||||
InChIKey |
FBSFWRHWHYMIOG-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 99-24-1
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Marbofloxacin | Chronic obstructive pulmonary disease | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Salmonella Typhimurium in rats were used in this study. | |||||
Experimental
Result(s) |
MG has shown to increase the antimicrobial activity of MAR in vitro and ex vivo experiments without affecting the pharmacokinetics of MAR in rats. |
